SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Halftone collage with hand chart. Growth finance business and marketing. Bright concept with halftone hand. Vector contemporary illustration
Autoimmune disease
Nektar Digs Into Mid-Stage Data to Establish Alopecia Efficacy of Rezpeg
Despite falling short of its primary Phase II objective, Nektar plans to push its T cell stimulator rezpeg into Phase III development.
December 17, 2025
 · 
2 min read
 · 
Tristan Manalac
A human hand and a robot hand shake hands over a white circle on a green background
Artificial intelligence
Roche Makes Good on Dealmaking Promise With $1.1B Caris Cancer Collab
Roche CEO Thomas Schinecker said during the company’s Q3 call that it is “not done” with deals—a promise he delivered on with Tuesday’s solid tumor pact with AI-focused Caris Life Sciences.
December 17, 2025
 · 
1 min read
 · 
Tristan Manalac
Poznan, Poland - 5 October 2024: GSK -Glaxosmithkline headquarters office building in Poznan.
Approvals
GSK Wins Asthma Approval for Anti-Inflammatory Antibody
The FDA rejected the use of Exdensur, however, for chronic rhinosinusitis with nasal polyps.
December 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Piggy bank rocket launcher with smoke trail on blue background. Savings growth concept. 3D Rendering, 3D Illustration
Startups
Addition Debuts With $100M to Advance One-Time Therapies for Rare, Chronic Diseases
Addition joins a growing list of launches this year, following in the footsteps of startups like Crystalys Therapeutics and Ollin Biosciences.
December 17, 2025
 · 
1 min read
 · 
Tristan Manalac
Podcast
Lilly’s Triple Triumph, Prasad’s COVID Error, J&J’s Surprise Voucher, M&A Targets
Eli Lilly’s retatrutide exceeds expectations in Phase III, capping off a sparkling 2025 for the obesity titan; an internal FDA safety review finds no confirmed pediatric deaths caused by COVID-19 vaccines, and Commissioner Marty Makary says no black box warning will be attached to the shots; and BioSpace looks at six biotechs that could be pharma’s next buy.
December 17, 2025
 · 
2 min read
 · 
Heather McKenzie
China High Resolution Innovation Concept
Insights
Uptick in Dealmaking, Chinese Partnerships Drive Biotech’s Comeback
Biotech’s slump may finally be over in 2026. In interviews with BioSpace, Zymeworks’ CEO Ken Galbraith and Zai Lab’s President and COO Josh Smiley explain what’s fueling the comeback.
December 17, 2025
 · 
3 min read
 · 
Jennifer Smith-Parker
A group of businessmen carry gold coins from a huge purse
Mergers & acquisitions
Pharmas Write Big M&A Checks Again as Patent Urgency Seizes C-Suites
2026 is set to be a banner year for M&A in biopharma, as buyers facing major patent cliffs fight for a small pool of late-stage assets.
December 17, 2025
 · 
5 min read
 · 
Annalee Armstrong
Yellow rubber ducks have metal rings fastened to their heads and one is being hooked on gradient blue background. Illustration of the concept of the traditional fairground stall game hook a duck
Mergers & acquisitions
6 Biotechs That Could Be Big Pharma’s Next M&A Target
Metsera showed the biopharma world that M&A is back. Who could be next?
December 17, 2025
 · 
8 min read
 · 
Annalee Armstrong
Two Fiery Fists In Impact With Stormy Sky In Background
Mergers & acquisitions
The 7 Most Impactful M&A Deals of 2025
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech.
December 17, 2025
 · 
7 min read
 · 
Dan Samorodnitsky
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS